OPT
NASDAQOpthea Limited
Price$3.30+0.00 (+0.00%)
2025-08-182025-11-18
Latest news
25 items- SECSEC Form 15F-12B filed by Opthea Limited15F-12B - Opthea Ltd (0001815620) (Filer)
- SECSEC Form 6-K filed by Opthea Limited6-K - Opthea Ltd (0001815620) (Filer)
- SECSEC Form 6-K filed by Opthea Limited6-K - Opthea Ltd (0001815620) (Filer)
- SECSEC Form S-8 POS filed by Opthea LimitedS-8 POS - Opthea Ltd (0001815620) (Filer)
- SECSEC Form 25 filed by Opthea Limited25 - Opthea Ltd (0001815620) (Filer)
- SECSEC Form 6-K filed by Opthea Limited6-K - Opthea Ltd (0001815620) (Filer)
- SECSEC Form 6-K filed by Opthea Limited6-K - Opthea Ltd (0001815620) (Filer)
- SECSEC Form 6-K filed by Opthea Limited6-K - Opthea Ltd (0001815620) (Filer)
- SECSEC Form 6-K filed by Opthea Limited6-K - Opthea Ltd (0001815620) (Filer)
- SECSEC Form 6-K filed by Opthea Limited6-K - Opthea Ltd (0001815620) (Filer)
- SECSEC Form 20-F filed by Opthea Limited20-F - Opthea Ltd (0001815620) (Filer)
- SECSEC Form 6-K filed by Opthea Limited6-K - Opthea Ltd (0001815620) (Filer)
- SECSEC Form 6-K filed by Opthea Limited6-K - Opthea Ltd (0001815620) (Filer)
- SECSEC Form 6-K filed by Opthea Limited6-K - Opthea Ltd (0001815620) (Filer)
- SECSEC Form 6-K filed by Opthea Limited6-K - Opthea Ltd (0001815620) (Filer)
- SECSEC Form 6-K filed by Opthea Limited6-K - Opthea Ltd (0001815620) (Filer)
- PROpthea Provides Corporate UpdateSuccessful DFA settlement reached Company with cash and cash equivalents of approximately USD20M Dr Fred Guerard, CEO, Tom Reilly, CFO, and Sujal Shah, Director, to step down Dr Jeremy Levin to continue as Chairman and to assume additional responsibilities as of September 1st MELBOURNE, Australia and PRINCETON, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), today provided a corporate update following the successful settlement of the Development Funding Agreement ("DFA") with the two investors under the DFA. DFA Settlement In March of 2025, after the primary endpoints were not met in both COAST and ShORe phase 3 clinical trials, Opthea
- SECSEC Form 6-K filed by Opthea Limited6-K - Opthea Ltd (0001815620) (Filer)
- SECSEC Form 6-K filed by Opthea Limited6-K - Opthea Ltd (0001815620) (Filer)
- SECSEC Form 6-K filed by Opthea Limited6-K - Opthea Ltd (0001815620) (Filer)
- PROpthea Announces Decision to Discontinue Wet AMD TrialsShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials Opthea continues to consider impact of negative trial results under its Development Funding Agreement (DFA) and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced updates on i
- ANALYSTOpthea Ltd. downgraded by H.C. Wainwright with a new price targetH.C. Wainwright downgraded Opthea Ltd. from Buy to Neutral and set a new price target of $2.00
- ANALYSTOpthea Ltd. downgraded by Leerink Partners with a new price targetLeerink Partners downgraded Opthea Ltd. from Outperform to Market Perform and set a new price target of $1.00 from $12.00 previously
- ANALYSTOpthea Ltd. downgraded by Jefferies with a new price targetJefferies downgraded Opthea Ltd. from Buy to Underperform and set a new price target of $1.00 from $8.00 previously
- ANALYSTOpthea Ltd. downgraded by OppenheimerOppenheimer downgraded Opthea Ltd. from Outperform to Perform
OPT FAQ
7 questionsWhat does Opthea Limited do?
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema...Where does OPT stock trade?
Opthea Limited (OPT) is listed on NASDAQ.What sector and industry is OPT in?
Opthea Limited operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Opthea Limited go public?
Opthea Limited (OPT) completed its IPO in 2020.What are analysts saying about OPT?
Opthea Limited has had 6 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral with a $200.00 price target on 2025-03-25.What companies are similar to OPT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare OPT side-by-side with any of them on Quantisnow.How can I track OPT on Quantisnow?
Quantisnow aggregates Opthea Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OPT to receive live email and push alerts on every new disclosure.